This site is intended for healthcare professionals in United Arab Emirates 




Sign InLog Out Our Medicines Therapy AreasExplore ContentExplore ContentDownloadable materialsVideosLet's ConnectLet's ConnectContact usPfizer medical information



AboutIntroducing EnbrelHeritage of EnbrelEMA approvalsTherapeutic IndicationsRheumatoid arthritisJuvenile idiopathic arthritisPsoriatic arthritisAxial spondyloarthritisPsoriasis & paediatric psoriasisMechanism of actionMechanism of actionHalf-lifeDosingDosingRheumatoid arthritis, psoriatic arthritis & axial spondyloarthritisJuvenile idiopathic arthritisPsoriasisPaediatric PsoriasisAdministration & storageAdministrationMYCLIC®StorageEfficacy & SafetyEfficacyRapid effectivenessSustained effectivenessEffectiveness with monotherapy or combination therapySafetyTolerability across indicationsImportant safety informationImmunogenicityImmunogenicity & clinical responseImmunogenicity & Enbrel®Experience & InsightsManufacturingManufacturingPatient storiesPatient stories: rheumatoid arthritisPatient with an increased risk of serious infectionsMTX-IR patientPatient who is considering starting a familyElderly-onset RA patientYoung patient worried about the lifelong impact of RAYoung patient worried about treatments that lose effectiveness over timePatient stories: juvenile idiopathic arthritisVery young patientPatient moving from childhood to adulthoodPatient stories: axial spondyloarthritisAS patient with heel enthesitisnr-axSpA patientAS patient with functional limitationsAdvanced AS patientPatient stories: psoriatic arthritis & psoriasisPso patient with severe symptoms Pso patient with cyclical symptoms PsA patient with metabolic syndromePsA patient with multiple skin and joint symptomsSupport your patientsSupport your patientsUsing Enbrel®
The Enbrel® MYCLIC® 
All the benefits of Enbrel at the click of a button1
Associated with greater independence2-5

Self-administration of Enbrel increased from 66% with the pre-filled syringe to 93% with MYCLIC*2

Easier to use2

93% of patients found MYCLIC easier to use than the pre-filled syringe*2​​​​​​​

Better tolerated2

Pain on injection was significantly reduced with mean VAS scores of 1.77 for MYCLIC vs 2.91 for the Enbrel pre-filled syringe (p<0.001)*2

Preferred by patients2

94.2% of patients chose MYCLIC over the pre-filled syringe as their preferred delivery device*2

Among 104 patients diagnosed with rheumatoid arthritis (56%), psoriatic arthritis (30%) or ankylosing spondylitis (14%) who were switched from the Enbrel 50 mg pre-filled syringe to the MYCLIC Auto-injector. Patients answered questions during an interview 2 months after switching.2VAS: Visual analogue scale.​​​​​​​
Enbrel®(etanercept) 25mg PFS, 50 mg PFS and 50 mg PFP. [Summary of Product Characteristics]. May 2021 for Qatar, Kuwait, UAE, and Bahrain. Enbrel® (etanercept) 25 mg PFS and 50 mg PFS. [Summary of Product Characteristics]. May 2021 for Oman.Borrás-Blasco J, et al. Expert Opin Biol Ther. 2013;13:1103-8.Malm K, et al. SAGE Open Medicine. 2017;5:1-8. Boeri M, et al. Patient Prefer Adherence. 2019;13:1093-110.Larsson I, et al. Int J Qualitative Stud Health Well-being. 2010;5. DOI: 10.3402/qhw.v5i2.5146.
Administration & storage

Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign inRegisterAccountSign Out

Copyright © 2023 Pfizer Gulf FZ LLC. All rights reserved.


i- The product information provided in this site is intended only for Healthcare Professionals of UAE. The products discussed herein may have different product labeling in different countries.


ii- The information provided on this website is intended only for healthcare professionals of UAE.